Combined treatment with paxalisib and mirdametinib significantly extends survival of SJ-DIPGX37-bearing mice.
Mr Newby, why is it that you apply one standard regarding NOX use of mouse trials, but don’t apply the same standard to KZA, with reference to the above MOUSE trial posted to the KZA board in July 2021?
- Forums
- ASX - By Stock
- Ann: Veyonda Survival Advantage in LuPSMA Therapy Confirmed
Combined treatment with paxalisib and mirdametinib significantly...
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $19.28M |
Open | High | Low | Value | Volume |
7.0¢ | 7.0¢ | 6.6¢ | $3.32K | 48.57K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 27044 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.0¢ | 4049 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 27044 | 0.066 |
3 | 122703 | 0.065 |
2 | 32786 | 0.061 |
4 | 105033 | 0.060 |
1 | 20000 | 0.059 |
Price($) | Vol. | No. |
---|---|---|
0.070 | 4049 | 1 |
0.072 | 10348 | 1 |
0.073 | 55111 | 2 |
0.079 | 11999 | 1 |
0.080 | 12099 | 2 |
Last trade - 12.31pm 10/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online